DrugBiological
Mepolizumab clinical trials
Also written Nucala and SB-240563.
Keep track of what changes. Save the mepolizumab studies recruiting or about to start, and get an email each week — studies that open, close, add sites or post results.
Watch these studiesHow studies write it
Studies that test it under each name
Studies by the year they started
66 studies that test it; most in 2017 (7)
| Year | Studies |
|---|---|
| 2001 | 1 |
| 2004 | 2 |
| 2005 | 2 |
| 2006 | 1 |
| 2007 | 1 |
| 2008 | 2 |
| 2009 | 1 |
| 2011 | 2 |
| 2012 | 5 |
| 2013 | 2 |
| 2014 | 5 |
| 2015 | 3 |
| 2016 | 3 |
| 2017 | 7 |
| 2018 | 1 |
| 2019 | 3 |
| 2020 | 3 |
| 2021 | 6 |
| 2022 | 4 |
| 2023 | 7 |
| 2024 | 3 |
| 2025 | 1 |
| 2026 | 1 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it.
- Asthma
- 21
Who runs them
Industry 32 · Other 34
GlaxoSmithKline (31) · McMaster University (2) · Mayo Clinic (2) · National Institute of Allergy and Infectious Diseases (NIAID) (2) · St. Paul's Sinus Centre (2) · Instituto de Investigación Marqués de Valdecilla (2) · Centre hospitalier de l'Université de Montréal (CHUM) (1) · Rigshospitalet, Denmark (1)
Often tested with
Tested in the same studies.
Studies
Open first, then newest update. How each study uses mepolizumab is read from its arms, and is right about nine times in ten.
Testing it · 66
- Mepolizumab and in Office-office Nasal Polypectomy in Patients With Chronic Rhinosinusitis (CRS).RecruitingPhase 4Instituto de Investigación Marqués de ValdecillaNCT07814924Written as Mepolizumab 100 MG
- Airway Dysfunction, Occlusions and Remodeling: COPD Patients and MepolizumabNot yet recruitingPhase 4Western University, CanadaNCT07749001Written as Mepolizumab 100 MG Injection
- Beyond EOsinophils: proteoMICS to Identify Potential Biomarker of Organ Damage and Response to MEPOLIZUMAB in EGPAEnrolling by invitationPhase 4Azienda Ospedaliero Universitaria di CagliariNCT07343661Written as Mepolizumab 100 MG Injection [Nucala]
- th2 Modulation CRSwNPNot yet recruitingPhase 4St. Paul's Sinus CentreNCT06107101Written as Mepolizumab
- Comparison of Immune Profiles in Chronic Rhinosinusitis Patients After Mepolizumab TreatmentRecruitingPhase 4St. Paul's Sinus CentreNCT05642806Written as Mepolizumab
- Mepolizumab and In-office Nasal Polypectomy in Patients With Chronic Rhinosinusitis (CRS). A Three Arm Study.Not yet recruitingPhase 4Instituto de Investigación Marqués de ValdecillaNCT05923047Written as Mepolizumab
- Immunological Basis for Mepolizumab Activity in COPDNot yet recruitingPhase 2Temple UniversityNCT05320939Written as Mepolizumab 100 MG
- Study of Mepolizumab-based Regimen Compared to Conventional Therapeutic Strategy in Patients With Eosinophilic Granulomatosis With Polyangiitis (E-merge)CompletedPhase 3Assistance Publique - Hôpitaux de ParisNCT05030155Written as Mepolizumab
- Identifying Predictors Of Response To Mepolizumab In CRSwNPActive, not recruitingPhase 4Centre hospitalier de l'Université de Montréal (CHUM)NCT05902325Written as Mepolizumab 100 MG Injection
- Mepolizumab as Add-on Treatment IN Participants With COPD Characterized by Frequent Exacerbations and Eosinophil LevelCompletedPhase 3GlaxoSmithKlineNCT04133909Written as Mepolizumab
- Effect of Mepolizumab in Severe Bilateral Nasal PolypsCompletedPhase 3GlaxoSmithKlineNCT03085797Written as Mepolizumab
- Efficacy and Safety of Mepolizumab in Adults With Chronic Rhinosinusitis With Nasal Polyps (CRSwNP)/ Eosinophilic Chronic Rhinosinusitis (ECRS)CompletedPhase 3GlaxoSmithKlineNCT04607005Written as Mepolizumab
- The Role of IL5 in Epithelial Cell IntegrityCompletedEarly Phase 1Johns Hopkins UniversityNCT05895929Written as Mepolizumab
- Study in Pediatrics With HypEREosinophilic Syndrome (SPHERE)CompletedPhase 3GlaxoSmithKlineNCT04965636Written as Mepolizumab
- A Pilot Study of the Use of 129Xe and 1H MRI to Measure the Modulation of Eosinophil-Related Inflammation by Mepolizumab In COPDCompletedPhase 3Sheffield Teaching Hospitals NHS Foundation TrustNCT05138250Written as Mepolizumab 100 MG
- Mepolizumab for COPD Hospital Eosinophilic Admissions Pragmatic TrialCompletedPhase 2/3University of LeicesterNCT04075331Written as Mepolizumab
- Aggravated Airway Inflammation: Research on Biological Treatment (Mepolizumab)CompletedPhase 4Helsinki University Central HospitalNCT04823585Written as Mepolizumab
- Mepolizumab in Chronic Obstructive Pulmonary Diseases (COPD) With Eosinophilic BronchitisCompletedPhase 3McMaster UniversityNCT01463644Written as Mepolizumab
- Mepolizumab for the Treatment of Chronic Cough With Eosinophilic Airways DiseasesCompletedPhase 4McMaster UniversityNCT04765722Written as Mepolizumab
- Mepolizumab for the Treatment of Chronic Spontaneous UrticariaCompletedEarly Phase 1Mayo ClinicNCT03494881Written as Nucala
See all 66 studies that test mepolizumab →
Given in every arm · 2 — mepolizumab is usual care beside what is tested
- Anti-IL-5 Therapy With Simple Polypectomy Versus Extended Endoscopic Sinus Surgery for CRSwNPNot yet recruitingPhase 4Eye & ENT Hospital of Fudan UniversityNCT07200336Written as Mepolizumab
- Mepolizumab to CRSwNP Through 12 Months - Randomised to FESS and Non-FESS Within the First 2 WeeksActive, not recruitingPhase 4Vibeke BackerNCT05598814Written as Mepolizumab Injection
As the comparator · 6 — what is tested is compared with mepolizumab
- Complete Remission After Treatment With Biologics for Nasal PolypsRecruitingPhase 4Rigshospitalet, DenmarkNCT07268313Written as NUCALA®
- A Study to Evaluate the Efficacy and Safety of SHR-1703 in Subjects With Eosinophilic Granulomatosis With Polyangiitis （EGPA）RecruitingPhase 2/3Guangdong Hengrui Pharmaceutical Co., LtdNCT05979051Written as Mepolizumab Injection
- Efficacy and Safety of Benralizumab in EGPA Compared to Mepolizumab.Active, not recruitingPhase 3AstraZenecaNCT04157348Written as Mepolizumab
- Efficacy and Safety of Depemokimab Compared With Mepolizumab in Adults With Relapsing or Refractory Eosinophilic Granulomatosis With Polyangiitis (EGPA)Active, not recruitingPhase 3GlaxoSmithKlineNCT05263934Written as Mepolizumab
- A Study of GSK3511294 (Depemokimab) Compared With Mepolizumab or Benralizumab in Participants With Severe Asthma With an Eosinophilic PhenotypeCompletedPhase 3GlaxoSmithKlineNCT04718389Written as Mepolizumab
- Study on Pharmacokinetics of Meperizumab Injection and NUCALA® in Healthy Male VolunteersStatus unknownEarly Phase 1Chia Tai Tianqing Pharmaceutical Group Co., Ltd.NCT05353179Written as NUCALA®
Codes
What other systems call mepolizumab · ClinicalTrials.gg INT004376
- MeSH (NLM) C434107mepolizumabConfirmed ClinicalTrials.gov, NLM, Wikidata
- UNII (FDA) 90Z2UF0E52MEPOLIZUMABConfirmed FDA, NLM, Wikidata
- RxNorm 1720597Confirmed FDA, Wikidata
- Wikidata Q3306175mepolizumabConfirmed FDA, NLM, Wikidata
- NCI Thesaurus C157376MepolizumabOne source FDA
- DrugBank DB06612One source Wikidata
| System | Code | Name there | Checked by |
|---|---|---|---|
| MeSH (NLM) | C434107 | mepolizumab | Confirmed ClinicalTrials.gov, NLM, Wikidata |
| UNII (FDA) | 90Z2UF0E52 | MEPOLIZUMAB | Confirmed FDA, NLM, Wikidata |
| RxNorm | 1720597 | — | Confirmed FDA, Wikidata |
| Wikidata | Q3306175 | mepolizumab | Confirmed FDA, NLM, Wikidata |
| NCI Thesaurus | C157376 | Mepolizumab | One source FDA |
| DrugBank | DB06612 | — | One source Wikidata |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.